{"entity":{"id":"ver001","kind":"drug","name":"VER001","aka":["Oral fulvestrant (VeraMorph)"],"tldr":"VER001 is an experimental tablet form of fulvestrant from VeraMorph, for hormone receptor-positive breast cancer that has spread. It is in laboratory testing.","summary":"VER001 is VeraMorph's oral formulation of fulvestrant, made with its DPOD delivery platform, intended for oestrogen receptor-positive metastatic breast cancer. NCI SBIR award 4R44CA306533-02 funds its preclinical validation. No human data have been published.","status":"preclinical","asOf":"2026-11-04","links":[{"label":"VeraMorph: product portfolio","url":"https://www.veramorph.com/portfolio"}],"tags":["pipeline"],"related":[],"cancers":[],"sections":[],"technologies":["oral-serds"],"targets":["estrogen-receptor"],"drugs":[],"companies":["veramorph"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo startup monitors","editedOn":"2026-11-04"},"code":"VER001","modality":"Oral selective oestrogen receptor degrader (fulvestrant reformulation)","mechanism":"Fulvestrant binds the oestrogen receptor and causes it to be degraded; VER001 is a formulation intended to deliver it by mouth rather than by injection.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/ver001/","neighbours":{"technology":[{"id":"oral-serds","kind":"technology","name":"Oral SERDs","route":"/technologies/oral-serds/"}],"target":[{"id":"estrogen-receptor","kind":"target","name":"Estrogen receptor (ERα)","route":"/targets/estrogen-receptor/"}],"company":[{"id":"veramorph","kind":"company","name":"VeraMorph","route":"/companies/veramorph/"}]}}